Mr Madan Raj Poudel

Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms

Event: ESC Congress 2024

Topic: Echocardiography

Session: Rare causes of heart failure

Access

Like

ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair

Event: ESC Congress 2024

Topic: Clinical

Session: Mechanical circulatory support

Access

Like

Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort

Event: ESC Congress 2020

Topic: Peripheral Artery Disease

Session: Peripheral Vascular and Cerebrovascular Disease ePosters

Access

Like

Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort

Event: ESC Congress 2019

Topic: Prevention

Session: Long term prognosis in coronary artery disease

Access

Like

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

Event: EuroPrevent 2019

Topic: Lipids

Session: Risk Factors and Prevention - Lipids

Access

Like

Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels

Event: ESC Congress 2018

Topic: Clinical, Other

Session: Aortic disease: clinical

Access

Like

First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up

Event: EuroPrevent 2018

Topic: Lipids

Session: Moderated Poster Session II

Access

Like

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

Event: EuroPrevent 2018

Topic: Lipids

Session: Lipids

Access

Like

Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting

Event: EuroPrevent 2018

Topic: Lipids

Session: Lipids

Access

Like

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

Event: EuroPrevent 2017

Topic: Lipids

Session: Diabetes/ Lipids/Obesity/Nutrition_Part 2

Access

Like

Mr Madan Raj Poudel

Contributor content

Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms

ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair

Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort

Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels

First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

ESC 365 is supported by

Mr Madan Raj Poudel Follow

Contributor content

Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms

ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair

Extremely elevated lipoprotein (a) as an independent risk factor for peripheral arterial disease in large patient cohort

Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

Aortic valve stenosis in patients with extremely elevated lipoprotein(a) levels

First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

ESC 365 is supported by

Mr Madan Raj Poudel